Physicochemical Properties
| Molecular Formula | C72H108F3N19O21S |
| Molecular Weight | 1664.80 |
| Related CAS # | Gap 26;197250-15-0 |
| Appearance | White to off-white solid powder |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In the three cell lines (SV-ARBEC, ECV304, and RBE4), gap 26 (0.25 mg/mL, 30 min) lowers the wave size. The InsP3-triggered ATP response is totally eliminated by Gap 26 (0.25) mg/mL, 30 min, and the ATP release is lowered to below the control level, suggesting that the basal ATP release is also impacted[1]. Although connexin 43 was present in the cell lines employed, gap 26 did not affect dye coupling through junctional channels, as demonstrated by the FRAP experiments[1]. However, gap 26 does severely decrease our InsP3-triggered intercellular calcium waves. The rabbit superior mesenteric arteries' rhythmic responses are dose-dependently reduced by gap 26 (100-300 μM), with an IC50 of 28.4 ± 3.4 μM[2]. |
| References |
[1]. Photoliberating inositol-1,4,5-trisphosphate triggers ATP release that is blocked by the connexin mimetic peptide gap 26. Cell Calcium. 2003 Jan;33(1):37-48. [2]. Peptides homologous to extracellular loop motifs of connexin 43 reversibly abolish rhythmic contractile activity in rabbit arteries. J Physiol. 1997 Aug 15;503 ( Pt 1):99-110. |
Solubility Data
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~60.07 mM) H2O :~50 mg/mL (~30.03 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (1.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 100 mg/mL (60.07 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6007 mL | 3.0034 mL | 6.0067 mL | |
| 5 mM | 0.1201 mL | 0.6007 mL | 1.2013 mL | |
| 10 mM | 0.0601 mL | 0.3003 mL | 0.6007 mL |